George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 Apr 11. doi: 10.1007/s41669-024-00483-w
Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7
Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3
Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Park EM, Tan X, Stephenson EM, Deal AM, Yopp JM, Rosenstein DL, Edwards T, Song MK. Psychometric analysis of the parenting concerns questionnaire in women with metastatic cancer. J Pain Symptom Manage. 2018 Feb;55(2):451-7. doi: 10.1016/j.jpainsymman.2017.09.021
Kosa KM, Cates SC, Ball M, Godwin SL, Coppings RJ. Consumers' response and preparedness to ensure food safety during extended power outages: findings from a national survey. International journal of food safety, nutrition and public health. 2014 Jul 17;5(1):34-45. doi: 10.1504/IJFSNPH.2014.063503
Jeuland M, Maskery B, Cook J, Poulos C, Clemens J, Lauria D, Stewart J, Lucas M, Whittington D. Incorporating cholera vaccine herd protection into economic cost-benefit and cost-effectiveness models. Procedia Vaccinol. 2010;2(2010):140-6. doi: 10.1016/j.provac.2010.07.006
Williams VSL, Smith M, Fehnel SE. The validity and utility of the BPI interference measures for evaluating the impact of osteoarthritic pain. J Pain Symptom Manage. 2006 Jan 1;31(1):48-57.
Neighbors DM, Bell TJ, Wilson J, Dodd SL. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage. 2001 Feb 1;21(2):129-43. doi: 10.1016/s0885-3924(00)00247-5.
Neighbors DM, Dodd SL. Re: economic evaluation of fentanyl - Response. J Pain Symptom Manage. 2001 Jan 1;22(1):541-3.